Plague

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:707A20.0A20.1A20.2
Who is this for?
Show terms as
3Active trials28Specialists8Treatment centers2Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Plague is a severe and potentially life-threatening infectious disease caused by the bacterium Yersinia pestis. It is not a genetic disorder but rather a zoonotic infection transmitted primarily through the bites of infected fleas that live on rodents, or through direct contact with infected animals or respiratory droplets from infected individuals. Plague is classified as a rare disease due to its low incidence in most parts of the world, though sporadic outbreaks continue to occur, particularly in parts of Africa, Asia, and the Americas. Plague manifests in three primary clinical forms. Bubonic plague (ICD-10: A20.0), the most common form, is characterized by painful, swollen lymph nodes called buboes, typically in the groin, axilla, or cervical region, accompanied by sudden onset of high fever, chills, headache, and severe malaise. Septicemic plague (A20.1) occurs when the bacteria spread to the bloodstream, causing disseminated intravascular coagulation, septic shock, and potentially gangrene of the extremities — historically giving rise to the name "Black Death." Pneumonic plague (A20.2) affects the lungs and is the most dangerous form, as it can be transmitted person-to-person via respiratory droplets and progresses rapidly to respiratory failure if untreated. Other forms include plague meningitis (A20.3) and pharyngeal plague. Without treatment, plague has a very high mortality rate, particularly for pneumonic and septicemic forms. However, early diagnosis and prompt antibiotic therapy dramatically improve outcomes. First-line treatments include streptomycin, gentamicin, doxycycline, and ciprofloxacin. Supportive care in an intensive care setting may be required for severe cases. Public health measures including flea control, rodent management, surveillance, and prophylactic antibiotics for exposed contacts are critical in outbreak settings. No widely available vaccine is currently in routine clinical use, though research into plague vaccines continues.

Also known as:

Clinical phenotype terms— hover any for plain English:

LymphadenitisHP:0002840CarbuncleHP:0020084ChillsHP:0025143Conjunctival hyperemiaHP:0030953DeliriumHP:0031258BacteremiaHP:0031864
Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

4 events
May 2026Testing of a New Rapid Antigen Test for Plague in Ituri, Democratic Republic of the Congo.

Institute of Tropical Medicine, Belgium

TrialNOT YET RECRUITING
Sep 2025Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age

Dynavax Technologies Corporation — PHASE2

TrialRECRUITING
May 2025Ph1, Randomized, Double-Blind and Controlled, Dose Escalation and Expansion Study to Assess the Safety and Pharmacokinetics of JST-010 in Healthy Adults

Just-Evotec Biologics — PHASE1

TrialRECRUITING
Aug 2020The Dental Care Revolution: Health Education Using AI or Humanized Counseling on Plague Control and Periodontal Treatment Outcome in Patients With Periodontal Disease

Kaohsiung Medical University Chung-Ho Memorial Hospital — NA

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Plague.

3 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

3 recruitingView all trials with filters →
Phase 21 trial
Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
Phase 2
Actively Recruiting
· Sites: Miami, Florida; El Dorado, Kansas +1 more · Age: 1855 yrs
Phase 11 trial
Ph1, Randomized, Double-Blind and Controlled, Dose Escalation and Expansion Study to Assess the Safety and Pharmacokinetics of JST-010 in Healthy Adults
Phase 1
Actively Recruiting
· Sites: Las Vegas, Nevada · Age: 1855 yrs
N/A1 trial
The Dental Care Revolution: Health Education Using AI or Humanized Counseling on Plague Control and Periodontal Treatment Outcome in Patients With Periodontal Disease
N/A
Actively Recruiting
PI: Hsiao-Ling Huang, Dr.PH (Kaohsiung Medical University, College of Dental Me) · Sites: Kaohsiung City · Age: 3565 yrs

Specialists

Showing 25 of 28View all specialists →
PM
Peter W Horby, MD
Specialist
PI on 1 active trial
GM
George Saviolakis, MD
BETHESDA, MD
Specialist
PI on 1 active trial1 Plague publication
KM
Kevin S. Griffith, MD, MPH
Specialist
PI on 1 active trial
MP
Martin Schriefer, PhD
Specialist
PI on 1 active trial
YB
Yuemei Hu, Bachelor
Specialist
PI on 5 active trials
KM
Kevin Griffith, MD, MPH
Specialist
PI on 1 active trial
IM
Issa Makumbi, MD
Specialist
PI on 1 active trial1 Plague publication
JM
John Jacobsen, MD
Specialist
PI on 1 active trial
GM
George Risi, MD
Specialist
PI on 1 active trial1 Plague publication
LM
L. Tyler Wadsworth, MD
Specialist
PI on 1 active trial1 Plague publication
EM
Edward Mbidde, MD
Specialist
PI on 1 active trial
IM
Ivor Emmanual, MD
Specialist
PI on 1 active trial1 Plague publication
KM
Keith Reisinger, MD
PITTSBURGH, PA
Specialist
PI on 1 active trial
SM
Steven Folkerth, MD
BEAVERCREEK, OH
Specialist
PI on 1 active trial
IM
Iaasc Marcadis, MD
Specialist
PI on 1 active trial1 Plague publication
VM
Vicki Grieff, MD
Specialist
PI on 1 active trial
RM
Richard Greenberg, MD
Specialist
PI on 1 active trial
RM
Richard N Greenberg, MD
Specialist
PI on 2 active trials
HD
Hsiao-Ling Huang, Dr.PH
Specialist
PI on 1 active trial
FM
Fengcai Zhu, Master
Specialist
PI on 3 active trials
EM
Eric Sheldon, MD
NORTHAMPTON, MA
Specialist
PI on 3 active trials
HD
HSIAO-LING HUANG, Dr.PH
Specialist
PI on 1 active trial
SM
sifan Yang, M.D.
Specialist
PI on 1 active trial
KW
KUAN YI WU
Specialist
PI on 4 active trials118 Plague publications
MM
Marina Reznik, MD, MS
BRONX, NY
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

2 resources

Rebyota

Ferring

C. diff infection

Unverified — confirm before calling
copay card
Copay CardPatient Assistance
Accepting applications

VOWST

Seres Therapeutics, Inc.

C. diff Infection

Unverified — confirm before calling
copay card
Copay CardPatient Assistance
Accepting applications

Travel Grants

No travel grants are currently matched to Plague.

Search all travel grants →NORD Financial Assistance ↗

Community

Open PlagueForum →

No community posts yet. Be the first to share your experience with Plague.

Start the conversation →

Latest news about Plague

Disease timeline:

New recruiting trial: The Dental Care Revolution: Health Education Using AI or Humanized Counseling on Plague Control and Periodontal Treatment Outcome in Patients With Periodontal Disease

A new clinical trial is recruiting patients for Plague

New recruiting trial: Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age

A new clinical trial is recruiting patients for Plague

New recruiting trial: Modifying PEST for Psoriatic Arthritis Screening

A new clinical trial is recruiting patients for Plague

New recruiting trial: Ph1, Randomized, Double-Blind and Controlled, Dose Escalation and Expansion Study to Assess the Safety and Pharmacokinetics of JST-010 in Healthy Adults

A new clinical trial is recruiting patients for Plague

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Plague

What is Plague?

Plague is a severe and potentially life-threatening infectious disease caused by the bacterium Yersinia pestis. It is not a genetic disorder but rather a zoonotic infection transmitted primarily through the bites of infected fleas that live on rodents, or through direct contact with infected animals or respiratory droplets from infected individuals. Plague is classified as a rare disease due to its low incidence in most parts of the world, though sporadic outbreaks continue to occur, particularly in parts of Africa, Asia, and the Americas. Plague manifests in three primary clinical forms. Bub

Are there clinical trials for Plague?

Yes — 3 recruiting clinical trials are currently listed for Plague on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Plague?

25 specialists and care centers treating Plague are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Plague?

2 patient support programs are currently tracked on UniteRare for Plague. See the treatments and support programs sections for copay assistance, eligibility, and contact details.